Aware Super Pty Ltd as trustee of Aware Super Buys 78,254 Shares of Gilead Sciences, Inc. $GILD

Aware Super Pty Ltd as trustee of Aware Super boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 177.8% during the second quarter, Holdings Channel.com reports. The firm owned 122,261 shares of the biopharmaceutical company’s stock after purchasing an additional 78,254 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super’s holdings in Gilead Sciences were worth $13,555,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at about $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,000 shares of company stock valued at $7,632,100 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $118.30 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a 50-day moving average of $115.00 and a two-hundred day moving average of $110.41. The stock has a market cap of $146.79 billion, a P/E ratio of 23.57, a P/E/G ratio of 0.81 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the business posted $2.01 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Citigroup lifted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.